Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2003 May;2(3):287-304.
doi: 10.1517/14740338.2.3.287.

Drug-induced cholestasis

Lakshumanan S Velayudham  1 , Geoffrey C Farrell
Affiliations
Review

Drug-induced cholestasis

Lakshumanan S Velayudham et al. Expert Opin Drug Saf. 2003 May.

Abstract

Drugs may cause several overlapping syndromes of cholestasis, the pathophysiological syndrome resulting from impaired bile flow. These reactions comprise approximately 17% of all hepatic adverse drug reactions (ADRs) and they may be severe. Causes of 'pure' (bland) cholestasis include oestrogens and anabolic steroids; rarer associations are with antimicrobials and NSAIDs. 'Cholestatic hepatitis' is a common drug reaction in which liver injury and inflammation cause significant elevation of serum alanine aminotransferase (ALT) as well as cholestasis. Chlorpromazine and ketoconazole are classic examples, but it is now exemplified by amoxycillin-clavulanate and other oxy-penicillins. Chronic cholestasis results from small bile duct injury leading to the vanishing bile duct syndrome (VBDS), a disorder mimicking primary biliary cirrhosis, or from injury to larger bile ducts causing secondary sclerosing cholangitis. Whilst there is increasing evidence of a genetic predisposition to cholestatic drug reactions, there are currently no pretreatment tests to predict drug safety. Prevention of severe reactions therefore relies on early detection of liver injury and prompt drug withdrawal. Symptomatic management includes relief of pruritus and correction of fat-soluble vitamin deficiency. In small cohort studies, ursodeoxycholic acid (UDCA) arrested progressive cholestasis in two-thirds of cases, but evidence for use of corticosteroids is anecdotal. This review considers diagnosis, pathogenesis, prevention and management of drug-induced cholestasis, with particular reference to frequently- and newly-described causes.

PubMed Disclaimer

Similar articles

  • [Clinicopathologic features of drug-induced vanishing bile duct syndrome].
    Ye LH, Wang CK, Zhang HC, Liu ZQ, Zheng HW. Ye LH, et al. Zhonghua Gan Zang Bing Za Zhi. 2017 Apr 20;25(4):317-320. doi: 10.3760/cma.j.issn.1007-3418.2017.04.019. Zhonghua Gan Zang Bing Za Zhi. 2017. PMID: 28494557 Chinese.
  • Drug-induced cholestasis.
    Larrey D, Erlinger S. Larrey D, et al. Baillieres Clin Gastroenterol. 1988 Apr;2(2):423-52. doi: 10.1016/0950-3528(88)90010-3. Baillieres Clin Gastroenterol. 1988. PMID: 3044469 Review.
  • Meropenem-induced vanishing bile duct syndrome.
    Schumaker AL, Okulicz JF. Schumaker AL, et al. Pharmacotherapy. 2010 Sep;30(9):953. doi: 10.1592/phco.30.9.953. Pharmacotherapy. 2010. PMID: 20812433
  • Drug-induced cholestasis.
    Erlinger S. Erlinger S. J Hepatol. 1997;26 Suppl 1:1-4. doi: 10.1016/s0168-8278(97)82326-4. J Hepatol. 1997. PMID: 9138122 Review.
  • Drug-induced bile duct injury.
    Visentin M, Lenggenhager D, Gai Z, Kullak-Ublick GA. Visentin M, et al. Biochim Biophys Acta Mol Basis Dis. 2018 Apr;1864(4 Pt B):1498-1506. doi: 10.1016/j.bbadis.2017.08.033. Epub 2017 Sep 4. Biochim Biophys Acta Mol Basis Dis. 2018. PMID: 28882625 Review.
See all similar articles

Cited by

See all "Cited by" articles

MeSH terms

LinkOut - more resources